First Time Loading...

Agios Pharmaceuticals Inc
NASDAQ:AGIO

Watchlist Manager
Agios Pharmaceuticals Inc Logo
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Watchlist
Price: 29.53 USD 0.34% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

AGIO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. [ Read More ]

The intrinsic value of one AGIO stock under the Base Case scenario is 27.17 USD. Compared to the current market price of 29.53 USD, Agios Pharmaceuticals Inc is Overvalued by 8%.

Key Points:
AGIO Intrinsic Value
Base Case
27.17 USD
Overvaluation 8%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Agios Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AGIO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Agios Pharmaceuticals Inc

Provide an overview of the primary business activities
of Agios Pharmaceuticals Inc.

What unique competitive advantages
does Agios Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Agios Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Agios Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Agios Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Agios Pharmaceuticals Inc.

Provide P/S
for Agios Pharmaceuticals Inc.

Provide P/E
for Agios Pharmaceuticals Inc.

Provide P/OCF
for Agios Pharmaceuticals Inc.

Provide P/FCFE
for Agios Pharmaceuticals Inc.

Provide P/B
for Agios Pharmaceuticals Inc.

Provide EV/S
for Agios Pharmaceuticals Inc.

Provide EV/GP
for Agios Pharmaceuticals Inc.

Provide EV/EBITDA
for Agios Pharmaceuticals Inc.

Provide EV/EBIT
for Agios Pharmaceuticals Inc.

Provide EV/OCF
for Agios Pharmaceuticals Inc.

Provide EV/FCFF
for Agios Pharmaceuticals Inc.

Provide EV/IC
for Agios Pharmaceuticals Inc.

Show me price targets
for Agios Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Agios Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Agios Pharmaceuticals Inc?

What are the Net Income projections
for Agios Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Agios Pharmaceuticals Inc?

What are the EPS projections
for Agios Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Agios Pharmaceuticals Inc?

What are the EBIT projections
for Agios Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Agios Pharmaceuticals Inc?

Compare the revenue forecasts
for Agios Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Agios Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Agios Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Agios Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Agios Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Agios Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Agios Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Agios Pharmaceuticals Inc.

Provide ROE
for Agios Pharmaceuticals Inc.

Provide ROA
for Agios Pharmaceuticals Inc.

Provide ROIC
for Agios Pharmaceuticals Inc.

Provide ROCE
for Agios Pharmaceuticals Inc.

Provide Gross Margin
for Agios Pharmaceuticals Inc.

Provide Operating Margin
for Agios Pharmaceuticals Inc.

Provide Net Margin
for Agios Pharmaceuticals Inc.

Provide FCF Margin
for Agios Pharmaceuticals Inc.

Show all solvency ratios
for Agios Pharmaceuticals Inc.

Provide D/E Ratio
for Agios Pharmaceuticals Inc.

Provide D/A Ratio
for Agios Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Agios Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Agios Pharmaceuticals Inc.

Provide Quick Ratio
for Agios Pharmaceuticals Inc.

Provide Current Ratio
for Agios Pharmaceuticals Inc.

Provide Cash Ratio
for Agios Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Agios Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Agios Pharmaceuticals Inc?

What is the current Free Cash Flow
of Agios Pharmaceuticals Inc?

Financials

Balance Sheet Decomposition
Agios Pharmaceuticals Inc

Current Assets 833.8m
Cash & Short-Term Investments 776.9m
Receivables 2.8m
Other Current Assets 54.1m
Non-Current Assets 103.3m
Long-Term Investments 29.4m
PP&E 69.8m
Other Non-Current Assets 4.1m
Current Liabilities 68m
Accounts Payable 9.8m
Accrued Liabilities 58.2m
Non-Current Liabilities 58.1m
Other Non-Current Liabilities 58.1m
Efficiency

Earnings Waterfall
Agios Pharmaceuticals Inc

Revenue
26.8m USD
Cost of Revenue
-2.9m USD
Gross Profit
23.9m USD
Operating Expenses
-415.4m USD
Operating Income
-391.5m USD
Other Expenses
39.4m USD
Net Income
-352.1m USD

Free Cash Flow Analysis
Agios Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

AGIO Profitability Score
Profitability Due Diligence

Agios Pharmaceuticals Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
Exceptional 3-Year Average ROE
Exceptional 1-Year Revenue Growth
39/100
Profitability
Score

Agios Pharmaceuticals Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

AGIO Solvency Score
Solvency Due Diligence

Agios Pharmaceuticals Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
High Altman Z-Score
74/100
Solvency
Score

Agios Pharmaceuticals Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AGIO Price Targets Summary
Agios Pharmaceuticals Inc

Wall Street analysts forecast AGIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AGIO is 43.66 USD with a low forecast of 29.29 USD and a high forecast of 51.45 USD.

Lowest
Price Target
29.29 USD
1% Downside
Average
Price Target
43.66 USD
48% Upside
Highest
Price Target
51.45 USD
74% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AGIO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AGIO Price
Agios Pharmaceuticals Inc

1M 1M
-2%
6M 6M
+38%
1Y 1Y
+31%
3Y 3Y
-47%
5Y 5Y
-48%
10Y 10Y
-28%
Annual Price Range
29.53
52w Low
19.97
52w High
34.81
Price Metrics
Average Annual Return -16.3%
Standard Deviation of Annual Returns 6.79%
Max Drawdown -72%
Shares Statistics
Market Capitalization 1.7B USD
Shares Outstanding 56 194 800
Percentage of Shares Shorted 11.89%

AGIO Return Decomposition
Main factors of price return

What is price return decomposition?

AGIO News

Other Videos

Company Profile

Agios Pharmaceuticals Inc Logo
Agios Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.7B USD

Dividend Yield

0%

Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 390 full-time employees. The company went IPO on 2013-07-24. The firm's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The firm is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.

Contact

MASSACHUSETTS
Cambridge
88 Sidney St
+16176498600.0
http://www.agios.com/

IPO

2013-07-24

Employees

390

Officers

CEO & Director
Mr. Brian M. Goff M.B.A.
Chief Financial Officer
Ms. Cecilia Jones
Corporate Secretary & Chief Legal Officer
Mr. James William Burns
Chief Medical Officer and Head of Research & Development
Dr. Sarah Gheuens M.D., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Dr. Craig B. Thompson M.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Shin-San Su Ph.D.
Show More
Principal Accounting Officer
Mr. T. J. Washburn Jr.
Chief Technical Operations Officer
Dr. Clive Patience Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one AGIO stock?

The intrinsic value of one AGIO stock under the Base Case scenario is 27.17 USD.

Is AGIO stock undervalued or overvalued?

Compared to the current market price of 29.53 USD, Agios Pharmaceuticals Inc is Overvalued by 8%.